Physician profile
Ryan E Morris
NPI 1750597415
$970.48
in general payments reported to CMS, 2019-2025
20 companies · $86.37 in 2025
The $86.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $97.64 · 2021: $131 · 2022: $181 · 2023: $174 · 2024: $54.08 · 2025: $86.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $232.99 | 2019-2025 | Farxiga, Airsupra |
| Medtronic, INC. | $91.06 | 2022-2023 | Corevalve Evolut R |
| Lilly USA, LLC | $84.90 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $80.45 | 2019-2022 | |
| Pfizer INC. | $75.82 | 2019-2025 | |
| Abbvie INC. | $64.29 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.58 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $51.08 | 2020-2021 | |
| Sanofi Pasteur INC. | $28.71 | 2022-2023 | |
| Allergan, INC. | $27.64 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.86 | 2019 | |
| Biogen, INC. | $19.87 | 2025 | Zurzuvae |
| Innovation Technologies INC | $19.33 | 2023 | Irrisept |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.09 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.24 | 2024 | Capvaxive, Gardasil 9, Vaqta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.86 | 2022 | |
| Mylan Specialty L.P. | $15.40 | 2021 | |
| Aytu Biopharma, INC. | $14.84 | 2019 | |
| Smith+Nephew, INC. | $14.27 | 2023 | Iodosorb Ointment 40g USA, Regranex, Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.